KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Current Liabilities (2020 - 2025)

Recursion Pharmaceuticals' Total Current Liabilities history spans 6 years, with the latest figure at $147.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 21.21% year-over-year to $147.7 million; the TTM value through Dec 2025 reached $147.7 million, down 21.21%, while the annual FY2025 figure was $147.7 million, 21.21% down from the prior year.
  • Total Current Liabilities reached $147.7 million in Q4 2025 per RXRX's latest filing, down from $155.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $187.5 million in Q4 2024 to a low of $26.9 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $98.5 million, with a median of $93.6 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: surged 227.19% in 2022, then fell 24.46% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $46.7 million in 2021, then skyrocketed by 114.89% to $100.3 million in 2022, then dropped by 7.08% to $93.2 million in 2023, then surged by 101.21% to $187.5 million in 2024, then decreased by 21.21% to $147.7 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Total Current Liabilities are $147.7 million (Q4 2025), $155.1 million (Q3 2025), and $164.0 million (Q2 2025).